Have you registered for next week's webinar? We will be joined by Zephyr Energy (ZPHR), SpectrumX, Scirocco Energy (SCIR) and Power Metal Resources (POW). The webinar is sponsored by PrimaryBid. Please register here.
Exciting times ahead. Been waiting for this for 15 months to start. Tabula Rasa next pls. 1 thing that i am puzzled about is the trial is meant to go on for a year ( as per RNS back in 2020 ) yet today the trial started and finishes in April 2022, thats 7 months approx and not 12 months. ???
Ok, this is from the VAL board, there appears to be a investors meet later this month for themselves? Some over there are putting 2+2 together and coming up with a deal materialising just before the meeting? Could be just plain ramping, however, as PYC and VAL are intrinsically linked via VAL201 and the max £6m PYC could receive, we'll have to keep an eye out.
In a perfect world, every share would have buyers and no sellers, but we do not live in that world, buyers and sellers make a market. Aim shares are like elevators, PI's are wanting to get in and out at different levels, and PYC is no different. We have to wait and be patient for news to arrive, there are at least 3 that are imminent and overdue. These are: Tablua/DosemeRx deal Prostate doisng APP to start at PTTU #VAL201 results due ( we are due up to £6m for that depending on deal )
PYC website seems to have been redesigned in parts? Meanwhile, over at VAL, they have a new house broker. Which could mean a uplift in activity, possible VAL201 deal & therefore PYC stand to make the maximum of £6m.
"Conventional drug development is a lengthy process, with an average time from lab discovery to market of about 12 years. Fewer than 10% of drug candidates make it past the first phase of clinical trials. Using data-driven hypothesis testing—often from new biological data—to discover new drugs and revitalize abandoned or failed compounds can significantly shorten this timeline and reduce development costs.
In the case of historically costly and time-consuming clinical trials, AI and big data-driven approaches to these challenges are poised to increase efficiencies, reduce costs, and bring life-saving medicines faster and in a more targeted manner to patients that can most benefit from that therapy.
Our ability to make an impact on healthcare—specifically on drug development—to benefit people and society will be enlarged and enhanced by AI in two ways. First, the timeline to bring new drugs to market will be greatly shortened resulting in lower development costs. The average cost of successfully bringing a drug to market was $2.6 billion in 2013. AI-designed drugs will eventually cut this cost dramatically both by reducing timelines and simultaneously reducing failure rates. Second, with reduced development costs and accelerated timelines for development, the ultimate cost to the patient and healthcare system will decrease as well while improving the benefit to patients globally.
We foresee a future in the coming years where dozens of new medicines (often for diseases that lack understanding or definition today) used in human clinical trials will be designed with AI. This will be the golden age of AI in medicine, resulting in an avalanche of new medicines along with the revitalization of existing drugs that benefit society and help to fulfill the promise of personalized medicine. "
Good post by PM2022 over on VAL highlighting work done by PYC au gratis. "The facts are that we are undervalued with proven drugs. With two phase 2 drugs and Val 301 a market cap of 13 million is very low. Throw in all the work by PYC as well and would they do all that for free if they thought it is worthless. Please also see broker report which backs up our low valuation.
A deal will significantly increase our market cap. Whether that happens or not is for others to judge but I have done my research and all looking good here. A deal to land very soon."
Today was excellent in the end. It started with it going in the red, then like a mirror image of yesterday it switched round and moved into positive territory and as Riddler says 150k at 7p near the close of play appears. Another heavy hitter (IMHO) has joined the PYC party on Twitter, the person in question rarely gets it wrong about the stocks they invest/trade with. Onwards and upwards.
Check on the drugs/packages that are on their website. Notice no mention of Docetaxel anywhere. The imminent partnership with TRHC could fill that gap. With Docetaxel being added to their suite of drugs, and the subscription models that are used in US Healthcare. Could be a absolute monster for PYC imho.